Abstract
The pathogenesis of inflammatory bowel disease is only partially understood; various environmental and host (e.g. genetic-, epithelial-, immune and non-immune) factors are involved. It is a multifactorial polygenic disease with probable genetic heterogeneity. Much of the recent emphasis in inflammatory bowel disease genetics research has been directed at the evaluation of candidate disease susceptibility genes within inflammatory bowel disease linkage intervals. Such studies have elucidated associations of numerous gene variants (e.g. NOD2/CARD15, SLC22A4/A5 and DLG5) with inflammatory bowel disease, but most of these require further replication and functional validation. Some genes are associated with inflammatory bowel disease itself, while others increase the risk of ulcerative colitis or Crohns disease or are associated with disease location and/or behaviour. Recently, some new data also indicated at a possible role for genetics in predicting therapeutic success (e.g. response to infliximab or steroids). Genetic information acquired in recent years helps in understanding the pathogenesis of inflammatory bowel disease and identifying a number of potential targets for therapeutic intervention. In the future, genetics may also help in more accurate diagnosis and prediction of disease course and response to therapy in inflammatory bowel disease.
Keywords: Inflammatory bowel disease, ulcerative colitis, Crohn's disease, thiopathogenesis, genetics, NOD2/CARD15, SLC22A4/A5, DLG5
Current Genomics
Title: Current Concepts on the Genetics and Pharmacogenetics of Inflammatory Bowel Disease: Do they Help in Clinical Management?
Volume: 7 Issue: 3
Author(s): Peter Laszlo Lakatos and Laszlo Lakatos
Affiliation:
Keywords: Inflammatory bowel disease, ulcerative colitis, Crohn's disease, thiopathogenesis, genetics, NOD2/CARD15, SLC22A4/A5, DLG5
Abstract: The pathogenesis of inflammatory bowel disease is only partially understood; various environmental and host (e.g. genetic-, epithelial-, immune and non-immune) factors are involved. It is a multifactorial polygenic disease with probable genetic heterogeneity. Much of the recent emphasis in inflammatory bowel disease genetics research has been directed at the evaluation of candidate disease susceptibility genes within inflammatory bowel disease linkage intervals. Such studies have elucidated associations of numerous gene variants (e.g. NOD2/CARD15, SLC22A4/A5 and DLG5) with inflammatory bowel disease, but most of these require further replication and functional validation. Some genes are associated with inflammatory bowel disease itself, while others increase the risk of ulcerative colitis or Crohns disease or are associated with disease location and/or behaviour. Recently, some new data also indicated at a possible role for genetics in predicting therapeutic success (e.g. response to infliximab or steroids). Genetic information acquired in recent years helps in understanding the pathogenesis of inflammatory bowel disease and identifying a number of potential targets for therapeutic intervention. In the future, genetics may also help in more accurate diagnosis and prediction of disease course and response to therapy in inflammatory bowel disease.
Export Options
About this article
Cite this article as:
Laszlo Lakatos Peter and Lakatos Laszlo, Current Concepts on the Genetics and Pharmacogenetics of Inflammatory Bowel Disease: Do they Help in Clinical Management?, Current Genomics 2006; 7 (3) . https://dx.doi.org/10.2174/138920206777780274
DOI https://dx.doi.org/10.2174/138920206777780274 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Guar Gum and HPMC Coated Colon Targeted Delivery of 6-Mercapto-Purine
The Natural Products Journal Alternative Therapy in the Prevention of Experimental and Clinical Inflammatory Bowel Disease. Impact of Regular Physical Activity, Intestinal Alkaline Phosphatase and Herbal Products
Current Pharmaceutical Design Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Cytokines, Inflammation and Colon Cancer
Current Cancer Drug Targets Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Desirability Based Optimization of New Mesalazine Modified Release Formulations: Compression Coated Tablets and Mini Tablets in Capsules
Letters in Drug Design & Discovery Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Diagnosis of Inflammatory Bowel Disease by Abdominal Ultrasound and Color Doppler Techniques
Current Medical Imaging Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Ulcerative Colitis: Pathogenesis
Current Drug Targets Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets Immune Abnormalities and Endotoxemia in Patients with Ulcerative Colitis and in Their First Degree Relatives: Attempts at Neutralizing Endotoxin- Mediated Effects
Current Pharmaceutical Design New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued)